Publications by authors named "L Bergkvist"

Article Synopsis
  • * In premenopausal patients, a high proportion (83.6%) received chemotherapy regardless of the axillary method used, but postmenopausal rates varied significantly by region, notably low in Denmark (36.0%).
  • * No significant difference in 5-year recurrence-free survival was found between the two axillary treatment groups for postmenopausal patients, suggesting a need for better strategies to avoid under-treatment while minimizing risks.
View Article and Find Full Text PDF

Importance: In patients with clinically node-negative (cN0) breast cancer and 1 or 2 sentinel lymph node (SLN) macrometastases, omitting completion axillary lymph node dissection (CALND) is standard. High nodal burden (≥4 axillary nodal metastases) is an indication for intensified treatment in luminal breast cancer; hence, abstaining from CALND may result in undertreatment.

Objective: To develop a prediction model for high nodal burden in luminal ERBB2-negative breast cancer (all histologic types and lobular breast cancer separately) without CALND.

View Article and Find Full Text PDF

Background: In luminal breast cancer, adjuvant CDK4/6 inhibitors (eg, abemaciclib) improve invasive disease-free survival. In patients with T1-2, grade 1-2 tumours, and one or two sentinel lymph node metastases, completion axillary lymph node dissection (cALND) is the only prognostic tool available that can reveal four or more nodal metastases (pN2-3), which is the only indication for adjuvant abemaciclib in this setting. However, this technique can lead to substantial arm morbidity in patients.

View Article and Find Full Text PDF

Background And Purpose: Recommendations for regional radiotherapy (RT) of sentinel lymph node (SLN)-positive breast cancer are debated. We here report a RT quality assessment of the SENOMAC trial.

Materials And Methods: The SENOMAC trial randomized clinically node-negative breast cancer patients with 1-2 SLN macrometastases to completion axillary lymph node dissection (cALND) or SLN biopsy only between 2015-2021.

View Article and Find Full Text PDF
Article Synopsis
  • A noninferiority trial was conducted to assess if omitting completion axillary-lymph-node dissection is as effective as performing it in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases.
  • A total of 2,766 patients were enrolled, with 1,335 assigned to sentinel-node biopsy only and 1,205 to the dissection group, with a median follow-up of 46.8 months.
  • The results showed a 5-year recurrence-free survival rate of 89.7% for the sentinel-node biopsy-only group, suggesting that this approach may not significantly compromise patient outcomes compared to the traditional method.
View Article and Find Full Text PDF